Novartis Faces First Generic Rival to Lutathera Following FDA Approval for Curium

Key Facts

1Novartis is now facing generic competition for its drug Lutathera from Curium's Bexlutry.

2The new competing drug targets gastroenteropancreatic neuroendocrine tumors.

Amid shifting dynamics in the pharmaceutical sector, Novartis has officially begun facing direct competition for its blockbuster drug Lutathera. According to reports, Curium has launched its generic alternative, Bexlutry, following FDA approval. This new competing drug targets gastroenteropancreatic neuroendocrine tumors, marking the first generic entry against Novartis's established radioligand therapy.

The introduction of generic alternatives typically signals long-term revenue erosion and pricing pressure for the original patent holder. Per market data, NVSEF shares closed at $134.75 (close September 14, 2026), having traded between a daily high of $137.41 and a low of $134.75. The entry of Curium into this specialized oncology niche represents a significant challenge to Novartis's market dominance in this category.

Traders should watch for the impact of this generic launch on Novartis's market share, with NVSEF currently at $134.75 (close September 14, 2026). While the economic calendar shows no sector-specific catalysts in the immediate 7-day window, the recent daily low of $134.75 may serve as a key support level to monitor as the market digests the long-term implications of this competitive threat.